Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis

计划入组 1,040 人 · 首次发布于 2005 年 9 月 22 日

A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI

计划入组 50 人 · 首次发布于 2025 年 12 月 17 日

Repurposing Lithium for Parkinson's Disease

计划入组 15 人 · 首次发布于 2023 年 10 月 25 日

chronic kidney disease therapy

Immune Modifying Particles

VGV-L

METABOLIC THERAPY, INC.

United States

Everads Therapy Ltd.

Israel

ATI Physical Therapy

United States

FDA Approves Zanvastro, First Disease-Modifying Therapy for Alexander Disease

FDA Approves Tzield as First Disease-Modifying Therapy for Type 1 Diabetes Prevention

TauRx's LMTX Shows Promising Results for Alzheimer's Treatment with Potential to Become First Oral Disease-Modifying Therapy